TriangleNCT00432094 · OUTCOME
Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Pre-Transplant
What was measured
Number of patients unable to achieve adequate stem cell mobilization, need to undergo one or tandem transplantation. Stem cell mobilization = A process in which certain drugs are used to cause the movement of stem cells from the bone marrow into the blood. The stem cells can be collected and stored. They may be used later to replace the bone marrow during a stem cell transplant.
Analysis population: The protocol is essentially one single-arm, but patients received either one or two transplants depending on the cells they had available and we are reporting results for these two groups.
Groups in this outcome
2 Transplants
Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens. carboplatin: Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes etoposide: 600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3. thiotepa: 150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4 autologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg) filgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
1 Transplant
Patients with Germ cell tumors who receive one transplant only. ifosfamide: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4. paclitaxel: 225 mg/m\^2 intravenous over 3 hours on Day -7. autologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg) Mesna: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4. filgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
| Group | Source count |
|---|---|
| 2 Transplants | 14 |
| 1 Transplant | 9 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| 2 Transplants | 0 | Not reported | Not reported | Not reported | Not reported |
| 1 Transplant | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 14
- group Id
- OG001
- value
- 9
- units
- Participants
- description
- Number of patients unable to achieve adequate stem cell mobilization, need to undergo one or tandem transplantation. Stem cell mobilization = A process in which certain drugs are used to cause the movement of stem cells from the bone marrow into the blood. The stem cells can be collected and stored. They may be used later to replace the bone marrow during a stem cell transplant.
- groups
- description
- Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens. carboplatin: Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes etoposide: 600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3. thiotepa: 150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4 autologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg) filgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
- id
- OG000
- title
- 2 Transplants
- description
- Patients with Germ cell tumors who receive one transplant only. ifosfamide: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4. paclitaxel: 225 mg/m\^2 intravenous over 3 hours on Day -7. autologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg) Mesna: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4. filgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
- id
- OG001
- title
- 1 Transplant
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- The protocol is essentially one single-arm, but patients received either one or two transplants depending on the cells they had available and we are reporting results for these two groups.
- reporting Status
- POSTED
- time Frame
- Pre-Transplant
- title
- Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice